Thousands of blood pressure pills recalled over quality issues
Blood pressure pills recalled nationwide after failing quality tests, potentially impacting patient treatment.
(Photo via Fox Business)
Macleods Pharma USA, Inc. has issued a nationwide recall for 3,744 bottles of prescription blood pressure medication after the tablets failed to meet dissolution specifications. The recall, which began on Oct. 7, 2026, involves medication that may not release into the body as intended, potentially resulting in ineffective blood pressure control.
The affected products are Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets in 40 mg, 10 mg, and 12.5 mg dosages. The recall includes 3,528 bottles of 30-count tablets under NDC 33342-246-07 and lot number 12251163A, as well as 216 bottles of 90-count tablets under NDC 33342-246-10 and lot number 12251163B. All recalled bottles have an expiration date of May 31, 2027.
On Oct. 26, 2026, the U.S. Food and Drug Administration classified the action as a Class II recall. This designation indicates that the use of the product may cause temporary or medically reversible adverse health consequences, though the probability of serious harm is considered remote.
The FDA advises patients to check their prescription bottles for the specified lot numbers and NDC codes. Officials emphasize that patients should not stop taking their medication without first consulting a healthcare provider, as abruptly discontinuing blood pressure treatment can pose significant health risks.